ASH 2022 | Phase I study of plamotamab in R/R NHL
Tycel Phillips, MD, City of Hope, Duarte, CA, shares insights into an ongoing Phase I dose-escalation study that is assessing the efficacy of plamotamab in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL; NCT02924402). Dr Phillips explains that plamotamab showed evidence of clinical activity, with a manageable safety profile. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting for Abbvie, AstraZeneca, Bayer, Beigene, BMS, Eli Lily, Epizyme, Genmab, Genentech, Gilead, Incyte, Pharmacyclics, Xencor Research support from Abbvie, Bayer, BMS, Incyte
